Shamim Ruff is VP at Sarepta Therapeutics, Inc. (SRPT). They have made 5 open-market trades across 2 companies since 2016, most recently 2023-09-26.
CIK 0001685986
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RETA | SELL · 10b5-1 | 2023-07-28 | 2023-08-01 | $164.53 | $2.7M | +0.9% | +1.8% | N/A |
| RETA | SELL | 2023-03-10 | 2023-03-13 | $83.73 | $961K | +3.5% | +13.5% | +16.6% |
| SRPT | SELL | 2017-11-06 | 2017-11-08 | $55.00 | $550K | +7.9% | +4.2% | +19.6% |
| SRPT | SELL | 2017-10-03 | 2017-10-05 | $50.00 | $575K | +2.1% | +9.6% | +15.6% |
| SRPT | SELL | 2017-07-20 | 2017-07-21 | $42.97 | $522K | -10.7% | -16.2% | +19.0% |
| SRPT | SELL | 2016-09-22 | 2016-09-30 | $60.00 | $439K | -13.1% | -36.4% | -55.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.